Research programme: hedgehog cell-signalling pathway inhibitors - Infinity

Drug Profile

Research programme: hedgehog cell-signalling pathway inhibitors - Infinity

Alternative Names: IPI-269609; IPI-609

Latest Information Update: 11 Mar 2013

Price : $50

At a glance

  • Originator Infinity Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Mar 2013 Discontinued - Preclinical for Cancer in USA (PO)
  • 14 Dec 2010 Infinity Pharmaceuticals and Mundipharma expand their strategic alliance agreement
  • 04 Nov 2010 Infinity Pharmaceuticals receives three grants under the US Government's Qualifying Therapeutic Discovery Project Programme to advance its three research programmes, including hedgehog pathway inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top